Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza

Completed · Phase 1 · Has a placebo group

Conditions studied: Influenza, Human

In brief

The purpose of this study is to compare the safety profile in healthy volunteers of a single intravenous administration of TCN-032 as compared with placebo.

Key facts

Study ID

NCT01390025

Run by

Theraclone Sciences, Inc.

People needed

40

Starts

2011-09-01

Expected to finish

2012-03-01

Last updated by the study team

2012-04-02

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy volunteers
• Normal lab tests

You may not qualify if…

• Prior treatment with a monoclonal antibody

Where it is running

• SNBL Clinical Pharmacology Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.